Yale SPORE in Lung Cancer News
New research from Yale Cancer Center provides a new understanding of patients’ views of artificial intelligence (AI) in healthcare. While comfort level varied by clinical application, most respondents had positive views about AI’s ability to improve care. Concerns surfaced when potential for misdiagnosis, privacy breaches, reduced time with clinicians, and increased costs were discussed.
- April 14, 2022
Roy S. Herbst, MD, PhD, has been appointed Chair of the American Association for Cancer Research (AACR) Scientific Policy and Government Affairs Committee; the appointment became effective at the AACR Annual Meeting earlier this week in New Orleans.
- March 15, 2022
A Yale Cancer Center research team has identified novel oncogenic gene fusions in lung and pancreatic cancer, as well as sarcoma. The fusions involve RASGRF1 (an activator of RAS signaling) and promote cellular changes leading to tumor development. The research is described online ahead of print in Clinical Cancer Research.
- February 22, 2022
CASE has elected a total of 35 new members, of whom 15 are from YSM/YSPH and three others are from FAS.
- October 07, 2021Source: Clinical Omics
Lee and colleagues found that adding an investigational AURKA inhibitor to sotorasib seemed to increase cancer cell death in sotorasib-resistant cancer cells. Adding WEE1 inhibition to AURKA inhibition also seemed to increase cancer cell death. “Our results suggest that AURKA activation may contribute to intrinsic and acquired resistance to sotorasib in KRAS-mutated lung cancer cells and that inhibition of AURKA may be a promising therapeutic approach in this setting,” said Lee.
- August 12, 2021
A new publication by Yale Cancer Center highlights recent breakthrough therapies developed to treat non-small cell lung cancer (NSCLC).
- April 26, 2021
As one of the highest honors in the scientific field, Lieping Chen, MD, PhD, United Technologies Corporation Professor in Cancer Research, Professor of Immunobiology, Dermatology, and of Medical Oncology, and Co-Director of the Cancer Immunology Program at Yale Cancer Center, was elected to the National Academy of Sciences (NAS).
- March 02, 2021Source: OneLive
Dr. Goldberg on the Toxicity Profile of Amivantamab in Metastatic EGFR Exon 20–Mutant NSCLC
- December 18, 2020
Based on results of a clinical trial led by Yale Cancer Center researchers, the U.S. Food and Drug Administration has approved osimertinib for the treatment of adults with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations, which occurs in about 10 percent of patients.
- October 07, 2020
Results of a new study led by Yale Cancer Center researchers shows the addition of cetuximab to afatinib versus afatinib alone did not improve outcomes in previously-untreated epidermal growth factor receptor mutant, non-small cell lung cancer.